Massimiliano Camilli: Mechanistic Insights Into Cardiovascular Risk Across Androgen Deprivation Therapies
Massimiliano Camilli, Member of the Atrial Disorders Committee of the Heart Failure Association of the ESC at European Society of Cardiology, shared a post on LinkedIn about a recent article by Antonia Beitzen-Heineke et al, published in JACC: CardioOncology, adding:
“Why might cardiovascular risk differ across androgen deprivation therapies?
A new prospective study in JACC: CardioOncology provides interesting mechanistic insights into the cardiovascular effects of androgen deprivation therapy in patients with prostate cancer.
Patients with prostate cancer already showed a heightened platelet activation and thromboinflammatory profile compared with healthy controls.
Importantly, the two ADT strategies appeared to have different effects:
- Leuprolide was associated with further increases in platelet reactivity across multiple agonist pathways.
- Relugolix, in contrast, did not increase platelet activation and was associated with reduced arachidonic acid–induced P-selectin and CD40 expression, alongside down-regulation of transcriptomic pathways involved in platelet activation and aggregation.
These findings provide a potential biological framework for the differences in cardiovascular outcomes observed across GnRH-based therapies and further highlight the complex interplay between cancer treatment, thrombosis, and cardiovascular risk.
An important step toward better understanding how the choice of anticancer therapy may influence cardiovascular health in patients with prostate cancer.”
Title: Divergent Effects of GnRH Agonist and GnRH Antagonist Treatment on Platelet Activity and Transcriptome
Authors: Antonia Beitzen-Heineke, Matthew Siskin, Matthew Muller, Anshini Bhatt, Kathryn C. Hafertepe, Yuhe Xia, Minas Economides, David R. Wise, Jeffrey S. Berger
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 16, 2026, 09:57Nathan Connell: A Regional Approach to Advancing Contemporary Hemophilia A Care
-
Sep 16, 2026, 09:20Mengistu Abate Belay: Bridging the Gap in Anemia Prevention During Pregnancy
-
Sep 16, 2026, 09:09Younes Kalakhy: When Normal Coagulation Tests Miss von Willebrand Disease
-
Sep 16, 2026, 09:00Test Your Knowledge of Warm Autoimmune Hemolytic Anemia – ASH Education
-
Sep 16, 2026, 08:28Jean Nakhle: Uncovering How Excess Cysteine Drives Cell Death
-
Sep 16, 2026, 08:20Heghine Khachatryan: Arterial and Venous Thrombosis May Require Different Approaches in Neonates
-
Sep 16, 2026, 07:57Tammuella Chrisentery-Singleton: Standing on the Shoulders of Giants in Hemophilia Care
-
Sep 16, 2026, 07:33Jakob Werner Hansen: Nordic VEX AZA Trial Reaches an Important Milestone
-
Sep 16, 2026, 06:54Jonathan Furniss: The Platelet Response That Helps Drive Tissue Repair